Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 62 entries
View as:

Multi-CAR-T Cells Targeting B Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT04429438 Org: User:
Start: 06/01/20 End: 12/31/23 Due: 12/31/24

4SCAR19U T Cells Targeting B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05995015 Org: User:
Start: 10/31/23 End: 12/31/26 Due: 12/31/27

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT04637503 Org: User:
Start: 11/18/20 End: 12/31/23 Due: 12/31/24

GD2/PSMA Bi-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05437315 Org: User:
Start: 06/30/22 End: 06/30/26 Due: 06/30/27

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04033302 Org: User:
Start: 09/01/19 End: 12/31/23 Due: 12/31/24

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Phase: N/A Priority: Normal
NCT ID: NCT03159364 Org: User:
Start: 07/15/17 End: 12/31/21 Due: 12/31/22

Universal CAR-T Cells Targeting AML

Phase: N/A Priority: Normal
NCT ID: NCT05995041 Org: User:
Start: 10/31/23 End: 12/31/26 Due: 12/31/27

Lentiviral FVIII Gene Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03217032 Org: User:
Start: 06/01/20 End: 06/01/22 Due: 06/01/23

CD19/22 Bi-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05432882 Org: User:
Start: 06/30/22 End: 06/30/26 Due: 06/30/27

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

Phase: N/A Priority: Normal
NCT ID: NCT05262673 Org: User:
Start: 03/01/22 End: 12/31/25 Due: 12/31/26

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05437341 Org: User:
Start: 06/30/22 End: 06/30/26 Due: 06/30/27

CD19/70 Bi-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05436496 Org: User:
Start: 06/30/22 End: 06/30/26 Due: 06/30/27

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04427449 Org: User:
Start: 06/01/20 End: 12/31/23 Due: 12/31/24

CAR-T Cells Targeting Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT05459870 Org: User:
Start: 07/31/22 End: 06/30/26 Due: 06/30/27

Combination Immunotherapy Targeting Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT04433221 Org: User:
Start: 07/01/20 End: 12/31/23 Due: 12/31/24

GD2/CD56 Bi-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05437328 Org: User:
Start: 06/30/22 End: 06/30/26 Due: 06/30/27

Combination Immunotherapy Targeting Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT06739226 Org: User:
Start: 12/10/24 End: 10/31/29 Due: 10/31/30

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03222674 Org: User:
Start: 07/15/17 End: 12/31/20 Due: 12/31/21

Direct Lentiviral Injection Gene Therapy for MLD

Phase: N/A Priority: Normal
NCT ID: NCT03725670 Org: User:
Start: 05/31/25 End: 12/31/30 Due: 12/31/31

Universal 4SCAR7U Targeting CD7-positive Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05995028 Org: User:
Start: 10/31/23 End: 12/31/26 Due: 12/31/27

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03125577 Org: User:
Start: 07/15/17 End: 12/31/21 Due: 12/31/22

HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Phase: N/A Priority: Normal
NCT ID: NCT03351855 Org: User:
Start: 11/15/17 End: 12/31/21 Due: 12/31/22

PSMA-specific CAR-T Cell Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04429451 Org: User:
Start: 01/01/20 End: 12/31/24 Due: 12/31/25

Intervention of Bladder Cancer by CAR-T

Phase: N/A Priority: Normal
NCT ID: NCT03185468 Org: User:
Start: 05/15/17 End: 12/31/20 Due: 12/31/21

Safety and Immunity of Covid-19 aAPC Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT04299724 Org: User:
Start: 02/15/20 End: 12/31/24 Due: 12/31/25